CA2353799A1 - Methods and compositions for inhibiting neoplastic cell growth - Google Patents

Methods and compositions for inhibiting neoplastic cell growth Download PDF

Info

Publication number
CA2353799A1
CA2353799A1 CA002353799A CA2353799A CA2353799A1 CA 2353799 A1 CA2353799 A1 CA 2353799A1 CA 002353799 A CA002353799 A CA 002353799A CA 2353799 A CA2353799 A CA 2353799A CA 2353799 A1 CA2353799 A1 CA 2353799A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
sequence identity
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353799A
Other languages
English (en)
French (fr)
Inventor
Avi J. Ashkenazi
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Scot A. Marsters
Mary A. Napier
Robert M. Pitti
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Application filed by Individual filed Critical Individual
Priority to CA002450402A priority Critical patent/CA2450402A1/en
Publication of CA2353799A1 publication Critical patent/CA2353799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002353799A 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth Abandoned CA2353799A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002450402A CA2450402A1 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting cancer cell growth comprising pro224

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
US60/113,296 1998-12-22
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
USPCT/US99/05028 1999-03-08
US13023299P 1999-04-21 1999-04-21
US60/130,232 1999-04-21
US13144599P 1999-04-28 1999-04-28
US60/131,445 1999-04-28
US13428799P 1999-05-14 1999-05-14
US60/134,287 1999-05-14
US14475899P 1999-07-20 1999-07-20
US60/144,758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
USPCT/US99/21090 1999-09-15
USPCT/US99/21547 1999-09-15
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/028565 WO2000037638A2 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002450402A Division CA2450402A1 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting cancer cell growth comprising pro224

Publications (1)

Publication Number Publication Date
CA2353799A1 true CA2353799A1 (en) 2000-06-29

Family

ID=27557838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353799A Abandoned CA2353799A1 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth

Country Status (13)

Country Link
EP (1) EP1141284A2 (de)
JP (5) JP3993746B2 (de)
KR (1) KR100499600B1 (de)
AT (2) ATE432987T1 (de)
AU (1) AU768230B2 (de)
CA (1) CA2353799A1 (de)
DE (2) DE69935085T2 (de)
DK (1) DK1484338T3 (de)
ES (2) ES2281704T3 (de)
IL (3) IL143031A0 (de)
MX (1) MXPA01006330A (de)
PT (1) PT1484338E (de)
WO (1) WO2000037638A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
WO1999027096A1 (en) 1997-11-22 1999-06-03 Hyseq, Inc. A NOVEL EGF MOTIF PROTEIN OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN
EP1251139A3 (de) * 1998-04-08 2002-12-18 Genentech, Inc. Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
KR100553300B1 (ko) * 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ATE368110T1 (de) * 1999-07-20 2007-08-15 Genentech Inc Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
MXPA02005758A (es) * 1999-12-09 2002-09-18 Sankyo Co Metodo para evaluar un remedio o agente preventivo para hiperlipidemia.
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP1325130B1 (de) 2000-10-06 2010-02-24 Yale University Homologe des nogo rezeptors
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2007008732A2 (en) 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
CA2648718A1 (en) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009137605A2 (en) 2008-05-06 2009-11-12 Genentech, Inc. AFFINITY MATURED CRIg VARIANTS
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate
CN114835774B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) * 2018-11-29 2022-03-22 株式会社東芝 電子装置

Also Published As

Publication number Publication date
DE69940964D1 (de) 2009-07-16
JP3993746B2 (ja) 2007-10-17
IL186154A0 (en) 2008-01-20
EP1141284A2 (de) 2001-10-10
MXPA01006330A (es) 2002-07-02
JP2007291116A (ja) 2007-11-08
AU1749900A (en) 2000-07-12
JP2007222180A (ja) 2007-09-06
DE69935085D1 (de) 2007-03-22
JP2003529317A (ja) 2003-10-07
ATE432987T1 (de) 2009-06-15
KR100499600B1 (ko) 2005-07-07
KR20010084882A (ko) 2001-09-06
DK1484338T3 (da) 2007-06-11
ES2281704T3 (es) 2007-10-01
AU768230B2 (en) 2003-12-04
ATE353339T1 (de) 2007-02-15
IL143031A0 (en) 2002-04-21
PT1484338E (pt) 2007-05-31
ES2327785T3 (es) 2009-11-03
JP2005237383A (ja) 2005-09-08
IL186153A0 (en) 2008-01-20
DE69935085T2 (de) 2007-08-23
WO2000037638A2 (en) 2000-06-29
JP2005245451A (ja) 2005-09-15
JP4037876B2 (ja) 2008-01-23
WO2000037638A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
AU768230B2 (en) Methods and compositions for inhibiting neoplastic cell growth
CA2373915A1 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2001007611A2 (en) Novel polynucleotides and method for the use thereof
WO2000075327A1 (en) Methods and compositions for inhibiting neoplastic cell growth
ZA200103885B (en) Methods and compositions for inhibiting neoplastic cell growth.
US20020010137A1 (en) Methods and compositions for inhibiting neoplastic cell growth
CA2348157A1 (en) Methods and compositions for inhibiting neoplastic cell growth
CA2390685C (en) Methods and compositions for inhibiting neoplastic cell growth
AU758462B2 (en) Methods and compositions for inhibiting neoplastic cell growth
AU2003213166B2 (en) Novel polypeptides having sequence similarity to GDNFR and nucleic acids encoding the same
WO2000075316A1 (en) Methods and compositions for inhibiting neoplastic cell growth
AU2003257515B2 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1820859B1 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
AU2003204815B2 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000053751A1 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1466977A1 (de) Verfahren und Zusammensetzungen zur Inhibierung des neoplastischen Zellwachstums
US20100285016A1 (en) PRO34128 nucleic acids
WO2000055319A1 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1518930A2 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem Zellwachstums
ZA200103883B (en) Method and compositions for inhibiting neoplastic cell growth.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued